Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.

PLoS computational biology - 1 Nov 2024

Roadnight Sheehan J, de Wijn Astrid S, Freire Thales Souza, Friedman Ran

Abstract excerpt

Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Drug selection in treatment of patients where the disease is showing resistance to therapy is often guided by IC50 or fold-IC50 values. In this work, through a model of the treatment of chronic myeloid leukaemia (CML), we contest using fold-IC50 values as a guide for treatment selection. CML is a blood cancer that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Drug Resistance, Neoplasm

Share to Inhibitory Concentration 50

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-abl

Source

Open in PubMed Open full text

Identifiers

PMID: 39509464
DOI: 10.1371/journal.pcbi.1012570
PMCID: PMC11575782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.PMID 39509464Read ↗

Beyond IC <sub>50</sub> - A computational dynamic model of drug resistance in enzyme inhibition treatmentSemantic proximity Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read ↗

A general framework for inhibitor resistance in protein kinases.Semantic proximity Read ↗

Drug resistance in cancer mechanisms and modelsSemantic proximity Read ↗

How to get rid of inhibitors.Semantic proximity Read ↗

Winning the arms race by improving drug discovery against mutating targets.Semantic proximity Read ↗

Pharmacodynamic model of PARP1 inhibition and global sensitivity analyses can lead to cancer biomarker discoverySemantic proximity Read ↗

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

Investigating the Role of Missense SNPs on ALDH 1A1 mediated pharmacokinetic resistance to cyclophosphamide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.